Legal

Supreme Court Rejects PIL Seeking CBI Probe Into Children’s Deaths From Toxic Cough Syrup

The Supreme Court has dismissed a public interest litigation (PIL) seeking a Central Bureau of Investigation (CBI) probe into the deaths of children caused by toxic cough syrup.

The bench, comprising Chief Justice BR Gavai and Justice K Vinod Chandran, delivered the verdict on Friday.

The PIL, filed by advocate Vishal Tiwari, alleged gross negligence in the manufacture and distribution of the syrup, with multiple deaths reported across several states, particularly Tamil Nadu.

The petition sought directives for a nationwide recall of toxic syrup products, suspension of sales, action against responsible officials, and the constitution of a national expert committee under the Supreme Court to strengthen drug safety mechanisms.

It also called for mandatory DEG/EG (diethylene glycol/ethylene glycol) testing of all syrup-based medications, compensation for victims, and a digital national drug recall portal to track and alert about fake or poisonous medicines.

Government Response

Solicitor General Tushar Mehta opposed the petition, stating that the petitioner filed it solely based on media reports and did not possess any official documents related to the incident.

He asserted that the PIL lacked the necessary factual foundation for CBI intervention.

Meanwhile, Tamil Nadu, Kerala, and Maharashtra governments had suspended the sale of the syrup within their jurisdictions, but multiple deaths had already occurred.

Investigations revealed that the product, manufactured by Sresan Pharma Pvt Ltd, contained 48.6 per cent diethylene glycol (DEG), a toxic substance responsible for the fatalities. Authorities have arrested Sresan Pharma’s director, Ranganathan Govindan, in connection with the case.

The syrup had been distributed to Madhya Pradesh, Rajasthan, Puducherry, and Odisha.

Authorities issued advisories to halt sales in these states. The Centre has also banned two other brands, Relief (Shep Pharma) and Respifresh (Rednex Pharmaceuticals).

The World Health Organisation (WHO) has noted the deaths and questioned the Indian government about the export of these syrups.

The PIL described the incident not as an isolated accident but as a result of institutional failures in India’s drug regulatory system.

Alleged lapses included inadequate testing of raw materials, negligence in batch releases, and poor adherence to quality standards over the 14 years Sresan Pharma operated its 2,000 sq ft facility on the Chennai–Bengaluru highway.

Also Read: Supreme Court Seeks Government Response On Voting Rights For Undertrial Prisoners

Gopal Krishna

Recent Posts

Allahabad High Court Bars Vending Zones Near Court Complex And Circuit House In Prayagraj

The Allahabad High Court has directed the Prayagraj Municipal Corporation to prevent urban markets and…

7 hours ago

Andaman And Nicobar LG Dr Dinesh Sharma Honours ITI Trainees At Fifth Skill Convocation

Lieutenant Governor Dr Dinesh Sharma attended the fifth Skill Convocation at ITI Dollygunj in Sri…

7 hours ago

PM Modi Says Citizens’ Response To Gold-Buying Appeal Helped Curb Prices

Prime Minister Narendra Modi said his year-long appeal to avoid unnecessary gold purchases received a…

7 hours ago

Amit Shah Credits PM Modi Government For Accelerating Northeast India’s Development Since 2014

Amit Shah outlined the infrastructure, connectivity, security and welfare initiatives undertaken in Northeast India since…

8 hours ago

PM Modi Says Vocational Skills And Education Will Shape India’s Future

Prime Minister Narendra Modi highlighted the importance of vocational training and academic education in nation-building.

9 hours ago

PM Modi’s Gamcha Diplomacy: How Traditional Indian Attire Shapes His Public Image And Regional Connect

Prime Minister Narendra Modi's frequent appearances with traditional Indian scarves and gamchas highlight the role…

9 hours ago